More and earlier use of long acting therapies (LATs) will help preserve functioning and prevent secondary treatment resistance,1 Professor Correll told the meeting. Compared with oral medication, LATs ensure drug delivery and reduce risk of relapse and mortality.1 There is also benefit from psychosocial interventions, he argued, and this was a theme explored earlier in the symposium by Silvana Galderisi (University of Campania Luigi Vanvitelli, Naples, Italy) who spoke of the need for a holistic approach to the treatment of schizophrenia.
In support of his view that health care professionals could do more to encourage use of LATs, Professor Correll referred to an analysis of 33 conversations between a psychiatrist and patients with schizophrenia.2 Only 9% of content focused on the benefits of an LAT; and only 33% of patients accepted its recommendation. Yet a subsequent interview found that 96% of patients who initially declined LAT were in fact receptive when the idea was more positively presented.
Focused staff training has the potential to substantially enhance the use of LAI antipsychotics
And to provide evidence that LATs could be widely accepted, he presented data from the recruitment phase of a recent US multicenter study.3 This involved a preparatory two-day training program for healthcare professionals and participating sites. This covered the rationale for LATs as relapse prevention in early psychosis, shared decision making, role playing, and solutions for overcoming logistical barriers. As a result, 77% of patients with first episode psychosis who were eligible for the trial received at least one long-acting injection.
Intervention early makes a difference
Earlier in the symposium, Ana Catalan (Basurto University Hospital, Bilbao, Spain) emphasized the importance of individualized treatment plans, of considering maintenance antipsychotic treatment, and of not forgetting psychosocial and psychotherapeutic interventions. She also strongly argued the case for early intervention services.
Meta-analysis of ten randomized clinical trials showed that early intervention was superior to treatment as usual in rates of therapy discontinuation, involvement in school or work, and severity of both positive and negative symptoms.4
Educational financial support for this satellite symposium at ECNP Virtual 2020 was provided by Janssen Pharmaceutica NV
For the latest updates on sea.progress.im, subscribe to our Telegram Channel https://bit.ly/telePiM